Every 8-K that Alphatec Holdings, Inc. (ATEC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ATEC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATEC filings page.
Alphatec Holdings reported solid Q2 2026 growth while remaining loss‑making on a GAAP basis. Total revenue was $214 million, up 15% year‑over‑year, with surgical revenue of $196 million, up 17% on 20% case volume growth. GAAP gross margin was 72.2%, and non‑GAAP gross margin was 72.5%.
Profitability metrics improved. Adjusted EBITDA was $36 million, a 16.8% margin and 420 basis‑point expansion year‑over‑year, and the company generated positive free cash flow, ending with $119 million in cash. Alphatec reported non‑GAAP net income of $11 million for the quarter. For 2026, it reaffirmed total revenue guidance of $882 million and raised adjusted EBITDA guidance to $140 million, while continuing to target at least $20 million of free cash flow.
Alphatec Holdings, Inc. held its 2026 annual meeting of stockholders on June 10, 2026, where stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan, making both plans effective upon approval.
Stockholders also elected seven directors for one-year terms, ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, and approved on a non-binding advisory basis the compensation of named executive officers. The meeting had 153,702,057 common shares outstanding as of the record date, with a quorum of 118,373,608 shares represented.
Alphatec Holdings, Inc. reported strong first-quarter 2026 growth and refinanced its debt with an inaugural syndicated bank facility. The new $175 million Term Loan A and $125 million revolver, led by JPMorgan and TD Securities, replace prior term loan and ABL facilities and extend maturities to 2031. At closing, the facility bears interest at SOFR plus 275 basis points and is expected to cut annual interest expense by more than $6 million, with over $35 million of potential savings over its life.
For the quarter ended March 31, 2026, total revenue reached $192 million, up from $169.2 million, with surgical revenue of $178 million growing 17% year over year on 21% case volume growth. GAAP gross margin was 71% and non‑GAAP gross margin 72%. GAAP operating expenses were $159 million, yielding a GAAP net loss of $33.9 million, or $0.22 per share, while non‑GAAP net income was roughly breakeven at $0.4 million.
Non‑GAAP adjusted EBITDA rose to $20.7 million, an 11% margin and a 460‑basis‑point expansion year over year. The company ended the quarter with $140 million in cash and reaffirmed 2026 surgical revenue guidance of about $805 million, while trimming EOS revenue to $77 million. It now targets total 2026 revenue of approximately $882 million, 15% growth, adjusted EBITDA of about $134 million (15% margin), and at least $20 million of free cash flow.
Alphatec Holdings, Inc. announced that longtime director Ward W. Woods chose to retire from its Board of Directors, effective February 27, 2026, for personal reasons. The company states his departure is not due to any disagreement regarding its operations, policies, or practices.
Mr. Woods, who also served on the Board’s Compensation Committee, entered into a Vesting Acceleration Agreement with Alphatec. Under this agreement, any restricted stock units granted to him on June 11, 2025 that remain unvested on his departure date will become fully vested. Following his resignation, the Board reduced its size from eight to seven directors to match the new composition.
Alphatec Holdings (ATEC) reported strong 2025 growth but remains loss-making on a GAAP basis. Full-year 2025 total revenue rose 25% to $764 million, with GAAP gross margin of 70%. Non-GAAP net income reached $8 million and adjusted EBITDA was $93 million, a 12% margin.
Fourth-quarter 2025 revenue was $213 million with adjusted EBITDA of $33 million, or 16% of revenue, and free cash flow of $8 million. Despite this, GAAP net loss for 2025 was $143 million. Cash and cash equivalents were $161 million at year-end.
For full-year 2026, Alphatec expects revenue to approximate $890 million, about 17% growth, including $805 million of surgical revenue and $85 million of EOS revenue. The company raised adjusted EBITDA guidance to about $134 million, or 15% margin, and anticipates generating at least $20 million of free cash flow.
Alphatec Holdings, Inc. furnished a current report to share that it has issued a press release with selected preliminary, unaudited financial information for the year ended December 31, 2025. The company notes that its year-end financial closing process is not yet complete, so the figures in the press release are estimates and may change, potentially in a material way, as closing adjustments are recorded. The press release is included as Exhibit 99.1, and the company specifies that this information is being furnished rather than filed under securities laws, which limits how it is treated for liability and incorporation into other filings.
Alphatec Holdings, Inc. (ATEC) reported a governance update. On November 7, 2025, the company announced the passing of Jeffrey P. Rydin, a valued member of its Board of Directors.
Alphatec furnished a related press release as Exhibit 99.1. The filing focuses on this board development and does not include financial results.
Alphatec Holdings, Inc. filed a Form 8‑K to furnish a press release announcing financial results for the period ended September 30, 2025. The disclosure is provided under Item 2.02.
The information, including Exhibit 99.1, is furnished and not filed and is not incorporated by reference. The company’s common stock (ticker ATEC) trades on the Nasdaq Global Select Market.